Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?

• In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity.
• The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo.
• Following discussions with the U.S. Food and Drug Administration, Roivant’s subsidiary, Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026.

Roivant Sciences (ROIV) on Friday reported encouraging Phase 2 clinical results for its experimental oral therapy brepocitinib in adults with cutaneous sarcoidosis, while also releasing its fiscal third quarter (Q3) earnings. 

The company reported a Q3 revenue of $1.9 million and a loss per share (EPS) of $0.38. Revenue came in below the analysts’ consensus estimate of $6.14 million, while EPS surpassed the consensus, according to Fiscal AI data. 

Positive BEACON Trial Outcomes 

In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity compared with placebo, demonstrating statistically meaningful benefits as early as four weeks and maintained through week 16.

The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo. Despite including the most treatment-resistant patients, the highest-dose group achieved rapid and sustained improvement.

Following the update, Roivant stock traded over 9% higher in Friday’s pre-market. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘normal’ message volume levels. 

Updates On Subsidiaries’ Therapy Programs

Following discussions with the U.S. Food and Drug Administration (FDA), Riovant’s subsidiary, Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026. The company has already submitted a New Drug Application for brepocitinib in dermatomyositis and expects additional Phase 3 data in non-infectious uveitis during the second half of 2026.

Additionally, the company said Immunovant’s IMVT-1402 program is fully enrolled in a late-stage rheumatoid arthritis study, with results anticipated in 2026. 

Meanwhile, the firm’s subsidiary Pulmovant’s mosliciguat trial in pulmonary hypertension linked to interstitial lung disease is also fully enrolled.

As of Dec. 31, 2025, Roivant reported approximately $4.5 billion in cash andequivalents.

ROIV stock has gained over 94% in the last 12 months. 

Also See: Nvidia Looks To End A Five-Day Losing Streak – Retail Believes ‘The Next Growth Wave Is Unfolding Now’

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on